Lifecore Signs Second Agreement to Supply DT-001 Batches for 2026 Phase 2 Acne Trials
Lifecore will produce engineering and clinical batches of DT-001 for Indomo’s ClearPen device to prepare for Phase 2 acne trials in 2026, its second development services contract with Indomo. The deal expands Lifecore’s CDMO business into autoinjector technologies and diversifies clients beyond ophthalmic therapies.
1. New CDMO Agreement Details
Lifecore will produce and supply engineering and clinical batches of DT-001 under a new development services agreement, representing its second collaboration with Indomo. This work supports planned studies designed to ready the corticosteroid formulation for Phase 2 clinical trials scheduled in 2026.
2. Strategic Expansion into Autoinjector Technologies
The contract marks a strategic move beyond Lifecore’s traditional focus on ophthalmic injectables into the rapidly growing autoinjector segment. By leveraging its sterile fill-and-finish capabilities, Lifecore aims to diversify its client base and capture additional CDMO revenue streams.
3. DT-001 Development and Market Potential
Indomo’s DT-001 combines triamcinolone acetonide with the ClearPen intradermal self-injection device for at-home treatment of inflammatory acne lesions. With acne affecting 50 million Americans annually and only one million receiving corticosteroid injections due to limited dermatologist access, the Phase 2 program targets a significant unmet need.